

Zuellig Pharma expands partnership with Lundbeck for commercialisation of neuro-psychiatric health solutions in Asia

16 December 2025 | News

Zuellig Pharma will commercialise Lundbeck's portfolio of products



Singapore-based Zuellig Pharma, a leading healthcare solutions company in Asia, has expanded its partnership with H. Lundbeck A/S, a biopharmaceutical company focusing exclusively on brain health.

Under this new agreement, Zuellig Pharma will take on the role of agency partner to commercialise Lundbeck's portfolio of products – including leading brands such as Lexapro[®], Brintellix[®] and Cipralex[®] – across Indonesia, Malaysia, the Philippines and Singapore. This builds on its existing distribution agreement with Lundbeck, under which Zuellig Pharma has been responsible for distributing the company's products in the four markets. In addition, Zuellig Pharma will also partner with Lundbeck in Taiwan.

As part of the expanded partnership, Zuellig Pharma will provide end-to-end commercialisation and healthcare services, including marketing and commercial execution, market access, distribution and supply chain management, medical information services, regulatory and quality support, as well as pharmacovigilance for Lundbeck's portfolio.